Corvus Pharmaceuticals, Inc.
Corvus Pharmaceuticals, Inc. is tracked here for clinical trial milestones, SEC filings and earnings dates. Focus area: Pharmaceutical Preparations.
The next scheduled catalyst is Next quarterly earnings (projected) on November 5, 2026, a projected date rather than a confirmed one. There are 4 upcoming events on record.
Cash runway is approximately 62.2 months based on the most recent reported cash position and quarterly operating burn as of 2026-06-30.
Across 7 concluded trials, 86% reached completion rather than being terminated or withdrawn.
| Date | Event | Type | Phase |
|---|---|---|---|
| November 5, 2026 est. | Next quarterly earnings (projected) | Earnings | — |
| June 15, 2027 | Study to Evaluate Soquelitinib in Participants With Moderate to Severe AD | Trial Milestone | Phase 2 |
| November 15, 2027 | Soquelitinib vs Standard of Care in Participants With Relapsed/Refractory Peripheral T-cell Lymphoma Not Otherwise Specified, Follicular Helper T-cell Lymphomas, or Systemic Anaplastic Large-cell Lymphoma | Trial Milestone | Phase 3 |
| December 15, 2027 | Safety and Efficacy of Soquelitinib in Adults With Hidradenitis Suppurativa | Trial Milestone | Phase 1 |
Track CRVS alongside other companies. Add it to a watchlist and see every catalyst on one calendar.
Open CRVS in the trackerTrial milestones come from the ClinicalTrials.gov v2 API, filings from SEC EDGAR, and financial figures from SEC XBRL company facts. Dates marked est. are projected rather than company-confirmed. This is an information tool, not investment advice — verify anything you act on against the linked primary source.
Last updated 2026-10-14.